Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2019
SIETES contiene 92806 citas

 
 
 1 a 16 de 16 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, Sidik SM, Lourido S, Langer R, Bavari S, Ploegh HL, Anderson DG. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proceedings of the National Academy of Sciences of the United States of America 2016;113:E4133-42. [Ref.ID 100595]
2.Tiene citas relacionadas Cita con resumen
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé GN, Soumah A, Trelle S, Vicari AS, Watson CH, Kieny MP, Rottingen J-A. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015;386:857-66. [Ref.ID 99512]
3.Tiene citas relacionadas Cita con resumen
Anónimo. An ebola vaccine: first results and promising opportunities. Lancet 2015;386:830. [Ref.ID 99511]
4. Cita con resumen
Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GL, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE, the RV 247 Study Team. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015;385:1545-54. [Ref.ID 99098]
5. Cita con resumen
Young K. Favipiravir shows some promise in early Ebola study. Journal Watch 2015:1. [Ref.ID 98771]
6.Tiene citas relacionadas Cita con resumen
Gupta-Wright A, Lavers J, Irvine S. Concerns about the off-licence use of amiodarone for Ebola. BMJ 2015;350:h272. [Ref.ID 98715]
7.Tiene citas relacionadas Cita con resumen
Turone F. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ 2014;349:g7198. [Ref.ID 98441]
8. Cita con resumen
Anónimo. Joint pain pauses Merck Ebola vaccine’s phase I. DIA Daily 2014:12 de diciembre. [Ref.ID 98386]
9. Cita con resumen
Anónimo. Swiss vaccine to treat Ebola approved for human trials. DIA Daily 2014:29 de octubre. [Ref.ID 98238]
10. Cita con resumen
Anónimo. Drugmakers banking on Ebola drug, vaccine stockpiling. DIA Daily 2014:27 de octubre. [Ref.ID 98201]
11.Enlace a cita original
Arie S. Ebola: an opportunity for a clinical trial?. BMJ 2014;349:g4997. [Ref.ID 98180]
12.Tiene citas relacionadas Cita con resumen
Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014;20:1126-9. [Ref.ID 98151]
13.Tiene citas relacionadas Cita con resumen
Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014;514:47-53. [Ref.ID 98150]
14. Cita con resumen
Anónimo. Drug manufacturers race to cure Ebola. DIA Daily 2014:20 de octubre. [Ref.ID 98121]
16. Cita con resumen
Goodman JL. Studying “secret serums” — Toward safe, effective Ebola treatments. N Engl J Med 2013;371:1086-9. [Ref.ID 97858]
Seleccionar todas
 
 1 a 16 de 16